Eyeworld

59 † $ PATIENTS PAY AS LITTLE AS Novartis AG owns the ILEVRO registered trademark and the ILEVRO logo trademark. Harrow IP, LLC owns the HARROW registered trademark and the HARROW logo trademark. IVRO-00066 08/24 © 2024 Harrow. All Rights Reserved. Reference: ILEVRO (nepafenac ophthalmic suspension) 0.3% Package Insert. Harrow IP LLC; 2023. INDICATIONS AND USAGE ILEVRO ® (nepafenac ophthalmic suspension) 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery. Dosage and Administration One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. IMPORTANT SAFETY INFORMATION Contraindications ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs). Adverse Reactions The most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5% to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. For additional information about ILEVRO ® 0.3%, please see the Brief Summary of Full Prescribing Information on the following page or visit ILEVROhcp.com. * Data provided through MMIT and are current as of 2/2024. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein. † Terms and conditions may apply. Copay program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. For full terms and conditions visit www.harrowconnects.com. LEARN MORE ABOUT THE HARROW SAVINGS PROGRAM Harrow is committed to helping patients have affordable access to ILEVRO ® ILEVRO ® has the best formulary coverage of any branded NSAID* EFFECTIVE. CONVENIENT. ACCESSIBLE. INFLAMMATION AND PAIN AT For your cataract surgery patients STRIKE

• Cover